General and Administrative Expense in USD of Enveric Biosciences, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Summary
Enveric Biosciences, Inc. quarterly/annual General and Administrative Expense history and growth rate from Q2 2010 to Q3 2025.
  • Enveric Biosciences, Inc. General and Administrative Expense for the quarter ending September 30, 2025 was $1.43M, a 19.7% increase year-over-year.
  • Enveric Biosciences, Inc. General and Administrative Expense for the twelve months ending September 30, 2025 was $6.13M, a 25.7% increase year-over-year.
  • Enveric Biosciences, Inc. annual General and Administrative Expense for 2024 was $6.45M, a 27.1% decline from 2023.
  • Enveric Biosciences, Inc. annual General and Administrative Expense for 2023 was $8.85M, a 23.7% decline from 2022.
  • Enveric Biosciences, Inc. annual General and Administrative Expense for 2022 was $11.6M, a 43.4% decline from 2021.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Growth (%)
General and Administrative Expense, Annual (USD)
General and Administrative Expense, YoY Annual Growth (%)

Enveric Biosciences, Inc. Quarterly General and Administrative Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $6.13M $1.43M +$235K +19.7% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-14
Q2 2025 $5.9M $1.22M -$29.1K -2.33% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $5.93M $1.36M -$526K -27.9% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $6.45M $2.12M +$1.57M +286% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-28
Q3 2024 $4.88M $1.2M -$885K -42.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-14
Q2 2024 $5.76M $1.25M -$2.02M -61.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 $7.79M $1.89M -$1.06M -36% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 $8.85M $550K -$2.27M -80.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-28
Q3 2023 $11.1M $2.08M -$1.43M -40.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $12.6M $3.27M +$772K +30.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $11.8M $2.95M +$181K +6.52% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $11.6M $2.82M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 $3.51M +$1.39M +65.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $2.5M +$192K +8.32% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $2.77M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q3 2021 $2.12M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $2.31M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q3 2017 $15.9M $5.28M +$3.96M +298% Jul 1, 2017 Sep 30, 2017 10-Q 2017-11-13
Q2 2017 $12M $4.41M +$2.43M +123% Apr 1, 2017 Jun 30, 2017 10-Q 2017-08-14
Q1 2017 $9.54M $2.7M +$983K +57.2% Jan 1, 2017 Mar 31, 2017 10-Q/A 2017-05-15
Q4 2016 $8.55M $3.53M -$170K -4.6% Oct 1, 2016 Dec 31, 2016 10-K/A 2017-04-04
Q3 2016 $8.72M $1.33M -$171K -11.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 $8.89M $1.98M +$1.49M +304% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 $7.41M $1.72M +$1.68M +4997% Jan 1, 2016 Mar 31, 2016 10-Q/A 2017-05-15
Q4 2015 $5.72M $3.7M +$4.25M Oct 1, 2015 Dec 31, 2015 10-K/A 2017-04-04
Q3 2015 $1.47M $1.5M +$1.49M +48001% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 -$21.8K $490K -$15.1K -2.99% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-12
Q1 2015 -$6.68K $33.7K +$26.1K +345% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
Q4 2014 -$32.8K -$548K -$508K -1259% Oct 1, 2014 Dec 31, 2014 10-K 2015-03-31
Q3 2014 $475K $3.11K -$1.44K -31.7% Jul 1, 2014 Sep 30, 2014 10-Q 2014-11-14
Q2 2014 $477K $505K +$501K +12870% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-18
Q1 2014 -$24.3K $7.58K +$2.89K +61.4% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-14
Q4 2013 -$27.2K -$40.4K -$50.4K -504% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-31
Q3 2013 $23.1K $4.56K -$9 -0.2% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-14
Q2 2013 $23.2K $3.89K -$190 -4.66% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 $23.3K $4.7K +$653 +16.1% Jan 1, 2013 Mar 31, 2013 10-Q/A 2014-05-08
Q4 2012 $22.7K $10K -$3K -23.1% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-28
Q3 2012 $25.7K $4.57K +$879 +23.8% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-06
Q2 2012 $24.8K $4.08K +$450 +12.4% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-01
Q1 2012 $24.4K $4.05K -$7.04K -63.5% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-02
Q4 2011 $31.4K $13K Oct 1, 2011 Dec 31, 2011 10-K 2013-02-28
Q3 2011 $3.69K -$1.93K -34.3% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-13
Q2 2011 $3.63K -$845 -18.9% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-01
Q1 2011 $11.1K Jan 1, 2011 Mar 31, 2011 10-Q/A 2012-05-10
Q3 2010 $5.61K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 $4.48K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-02

Enveric Biosciences, Inc. Annual General and Administrative Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $6.45M -$2.4M -27.1% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-28
2023 $8.85M -$2.75M -23.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-28
2022 $11.6M -$8.89M -43.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-26
2021 $20.5M Jan 1, 2021 Dec 31, 2021 10-K/A 2023-06-09
2016 $8.55M +$2.83M +49.5% Jan 1, 2016 Dec 31, 2016 10-K/A 2017-04-04
2015 $5.72M +$5.75M Jan 1, 2015 Dec 31, 2015 10-K/A 2017-04-04
2014 -$32.8K -$5.6K -20.6% Jan 1, 2014 Dec 31, 2014 10-K 2015-03-31
2013 -$27.2K -$49.9K -220% Jan 1, 2013 Dec 31, 2013 10-K 2015-03-31
2012 $22.7K -$8.71K -27.7% Jan 1, 2012 Dec 31, 2012 10-K 2014-03-28
2011 $31.4K -$4.48K -12.5% Jan 1, 2011 Dec 31, 2011 10-K 2013-02-28
2010 $35.9K Jan 1, 2010 Dec 31, 2010 10-K 2012-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.